

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 10:14:36 ON 04 AUG 2006  
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 10:14:36 ON 04 AUG 2006  
Compendex Compilation and Indexing (C) 2006  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 10:14:36 ON 04 AUG 2006  
COPYRIGHT (c) 2006 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 10:14:36 ON 04 AUG 2006  
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 10:14:36 ON 04 AUG 2006  
COPYRIGHT (c) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 10:14:36 ON 04 AUG 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> glycophorin and heart failure and antibody

L1 1 FILE CAPLUS  
L2 0 FILE BIOTECHNO  
L3 0 FILE COMPENDEX  
L4 0 FILE ANABSTR  
L5 0 FILE CERAB  
L6 0 FILE METADEX  
L7 100 FILE USPATFULL

TOTAL FOR ALL FILES

L8 101 GLYCOPHORIN AND HEART FAILURE AND ANTIBODY

=> d l1 ibib abs total

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409131 CAPLUS

DOCUMENT NUMBER: 142:445553

TITLE: Methods for quantification of circulating  
glycophorin in body fluids for diagnosis of  
congestive heart failure

INVENTOR(S): Jackowski, George; Van Lieshout, Tracy; Thatcher,  
Brad; Zhang, Rulin; Yantha, Jason; Rasamoeliso,  
Michele

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005100964	A1	20050512	US 2003-706599	20031111
AU 2004287908	A1	20050519	AU 2004-287908	20041110
WO 2005045436	A1	20050519	WO 2004-CA1945	20041110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1641cxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

*please scan*

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
  
NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:14:19 ON 04 AUG 2006

=> file .chemistry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 10:14:36 ON 04 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-706599 A 20031111  
WO 2004-CA1945 W 20041110

AB The invention provides methods for quantification of circulating  
glycophorin in body fluids for diagnosis of congestive  
heart failure including ELISA and SELDI-TOF. The  
circulating glycophorin measured by this assay is a truncated  
glycophorin diagnostic for congestive heart  
failure (CHF).

=> glycophorin and heart failure

L9 1 FILE CAPLUS  
L10 0 FILE BIOTECHNO  
L11 0 FILE COMPENDEX  
L12 0 FILE ANABSTR  
L13 0 FILE CERAB  
L14 0 FILE METADEX  
L15 100 FILE USPATFULL

TOTAL FOR ALL FILES

L16 101 GLYCOPHORIN AND HEART FAILURE

=> file .jacob

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.53	24.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'CAPLUS' ENTERED AT 10:15:37 ON 04 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:15:37 ON 04 AUG 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 10:15:37 ON 04 AUG 2006

FILE 'EMBASE' ENTERED AT 10:15:37 ON 04 AUG 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 10:15:37 ON 04 AUG 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> glycophorin and heart failure

L17 1 FILE CAPLUS  
L18 1 FILE BIOSIS  
L19 1 FILE MEDLINE  
L20 2 FILE EMBASE  
L21 100 FILE USPATFULL

TOTAL FOR ALL FILES

L22 105 GLYCOPHORIN AND HEART FAILURE

=> dup rem

ENTER L# LIST OR (END):117-120

PROCESSING COMPLETED FOR L17

PROCESSING COMPLETED FOR L18

PROCESSING COMPLETED FOR L19

PROCESSING COMPLETED FOR L20

L23 3 DUP REM L17-L20 (2 DUPLICATES REMOVED)

=> d l23 ibib abs total

L23 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409131 CAPLUS

DOCUMENT NUMBER: 142:445553

TITLE: Methods for quantification of circulating  
glycophorin in body fluids for diagnosis of  
congestive heart failure

INVENTOR(S): Jackowski, George; Van Lieshout, Tracy; Thatcher,  
Brad; Zhang, Rulin; Yantha, Jason; Rasamoelisololo,  
Michele

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005100964	A1	20050512	US 2003-706599	20031111
AU 2004287908	A1	20050519	AU 2004-287908	20041110
WO 2005045436	A1	20050519	WO 2004-CA1945	20041110
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-706599 A 20031111  
WO 2004-CA1945 W 20041110

AB The invention provides methods for quantification of circulating  
glycophorin in body fluids for diagnosis of congestive  
heart failure including ELISA and SELDI-TOF. The  
circulating glycophorin measured by this assay is a truncated  
glycophorin diagnostic for congestive heart  
failure (CHF).

L23 ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights  
reserved on STN

ACCESSION NUMBER: 2004462644 EMBASE

TITLE: Altered glycosylation leads to Tr polyagglutination.

AUTHOR: Halverson G.R.; Lee A.H.; Oyen R.; Reiss R.F.;  
Hurlet-Jensen A.; Reid M.E.

CORPORATE SOURCE: Dr. M.E. Reid, New York Blood Center, 310 East 67th Street,  
New York, NY 10021, United States. mreid@nybloodcenter.org

SOURCE: Transfusion, (2004) Vol. 44, No. 11, pp. 1588-1592. .

Refs: 29

ISSN: 0041-1132 CODEN: TRANAT

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 025 Hematology  
026 Immunology, Serology and Transplantation  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 12 Nov 2004  
Last Updated on STN: 12 Nov 2004

AB BACKGROUND: Polyagglutination refers to red blood cells (RBCs) that are agglutinated by a high proportion of ABO-matched adult sera but not by cord sera. Polyagglutinable RBCs have been associated with microbial infection, myeloproliferative disorders, and myelodysplasia. Lectins aid in the identification of polyagglutination. CASE STUDY: A Hispanic male infant with mild hemolytic anemia, a "Bernard-Soulier-like" syndrome, intermittent neutropenia, mitral valve regurgitation, ligament hyperlaxity, and mild mental retardation was studied. The patient's Group O RBCs were polyagglutinable; they were agglutinated by normal human sera, several lectins [including *Arachis hypogea*, *Salvia sclarea*, *Salvia horminum*, *Glycine max*, *Ulex europaeus*, *Griffonia simplicifolia* I, and *Gr. simplicifolia* II], and some monoclonal antibodies. His RBCs were not agglutinated by cord sera, *Dolichos biflorus*, or *Phaseolus lunatus*. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis on the RBC membranes followed by staining with periodic acid-Schiff stain showed markedly reduced staining of glycophorins A and B. Staining with Coomassie brilliant blue revealed that Band 3 has a faster mobility than normal. CONCLUSIONS: Collectively, the results suggest that the patient's RBCs have a reduction in N-acetylneuraminic acid on both N- and O-glycans, exposing, respectively,  $\beta$ 1,4-galactosidase and  $\beta$ 1,3-galactosidase. The patient likely has an altered glycosyltransferase that results in defective glycosylation in RBCs and other cell lineages. This type of polyagglutination was named Tr.

L23 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
DUPLICATE 1

ACCESSION NUMBER: 2001:327281 BIOSIS  
DOCUMENT NUMBER: PREV200100327281  
TITLE: Hematopoiesis/erythropoiesis in myocardial infarcts.  
AUTHOR(S): Goldman, Bruce I. [Reprint author]; Wurzel, John  
CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, Temple  
University Medical School, 3400 N. Broad St., Philadelphia,  
PA, 19140, USA  
goldmanb@astro.ocis.temple.edu  
SOURCE: Modern Pathology, (June, 2001) Vol. 14, No. 6, pp. 589-594.  
print.  
ISSN: 0893-3952.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 11 Jul 2001  
Last Updated on STN: 19 Feb 2002

AB Extramedullary hematopoiesis occurring in the myocardium has previously only been reported in a single case of a neonate with cyanotic congenital heart disease. Herein we report the incidental discovery of extramedullary hematopoiesis or pure erythropoiesis in four failing adult hearts with myocardial infarction. In two cases, extramedullary hematopoiesis or erythropoiesis was identified in cardiectomy specimens removed at orthotopic heart transplantation; in two other cases, erythropoiesis was found in left ventricular tissue removed at the time of implantation of left ventricular assist devices. Myocardial hematopoiesis/erythropoiesis was identified based on characteristic light-microscopic findings in routinely processed tissue and was confirmed by immunohistochemistry using monoclonal antibodies to the erythroid cell marker glycophorin A (positive in all cases), the megakaryocyte marker CD61, and the granulocyte marker neutrophil elastase (the latter two markers positive in one case only). None of the four patients had a myeloproliferative disorder or evidence of a myelophthisic process. No hematopoietic elements were identified in 109 cardiectomy specimens

without acute or recent infarcts. Myocardial hematopoiesis or erythropoiesis could represent heretofore-unrecognized manifestations of altered cytokine expression in patients with heart failure due to myocardial infarction.

=> glycophorin(10A)antibody

L24 263 FILE CAPLUS  
L25 259 FILE BIOSIS  
L26 244 FILE MEDLINE  
L27 219 FILE EMBASE  
L28 195 FILE USPATFULL

TOTAL FOR ALL FILES

L29 1180 GLYCOPHORIN(10A) ANTIBODY

=> glycophorin(5A)antibody

L30 221 FILE CAPLUS  
L31 197 FILE BIOSIS  
L32 185 FILE MEDLINE  
L33 167 FILE EMBASE  
L34 163 FILE USPATFULL

TOTAL FOR ALL FILES

L35 933 GLYCOPHORIN(5A) ANTIBODY

=> l34 and residue and (5-25 or 39-45 or 107-119)

L36 0 FILE CAPLUS  
L37 0 FILE BIOSIS  
L38 0 FILE MEDLINE  
L39 0 FILE EMBASE  
L40 10 FILE USPATFULL

TOTAL FOR ALL FILES

L41 10 L34 AND RESIDUE AND (5-25 OR 39-45 OR 107-119)

=> dup rem

ENTER L# LIST OR (END):l40

PROCESSING COMPLETED FOR L40

L42 10 DUP REM L40 (0 DUPLICATES REMOVED)

=> d l42 ibib abs total

L42 ANSWER 1 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2005:117697 USPATFULL

TITLE: Diagnostic methods for congestive heart failure

INVENTOR(S): Jackowski, George, Kettleby, CANADA

Van Lieshout, Tracy, Hamilton, CANADA

Thatcher, Brad, Casalnuovo de Napoli, ITALY

Zhang, Rulin, Brampton, CANADA

Yantha, Jason, Toronto, CANADA

Rasamoelisololo, Michele, Winnipeg, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005100964	A1	20050512
APPLICATION INFO.:	US 2003-706599	A1	20031111 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCHALE & SLAVIN, P.A., 2855 PGA BLVD, PALM BEACH GARDENS, FL, 33410, US		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		

LINE COUNT: 699

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an assay for the quantification of circulating glycoporphin in biological fluid samples. The circulating glycoporphin measured by this assay is a truncated glycoporphin diagnostic for congestive heart failure (CHF).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:88263 USPATFULL

TITLE: Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays

INVENTOR(S): Banchereau, Jacques F., Dallas, TX, UNITED STATES  
Palucka, Anna Karolina, Dallas, TX, UNITED STATES  
Blanco, Patrick, Talence, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067232	A1	20040408
APPLICATION INFO.:	US 2003-466023	A1	20030707 (10)
	WO 2002-US343		20020108
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Jane M Love, Hale and Dorr, 300 Park Avenue, New York, NY, 10022		
NUMBER OF CLAIMS:	52		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	1925		

AB The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

L42 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:77080 USPATFULL

TITLE: Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof

INVENTOR(S): Bay, Sylvie, Paris, FRANCE  
Cantacuzene, Daniele, Paris, FRANCE  
Leclerc, Claude, Paris, FRANCE  
Lo-Man, Richard, Paris, FRANCE  
Vicher-Guerre, Sophie, La Celle Saint Cloud, FRANCE  
PATENT ASSIGNEE(S): INSTITUT PASTEUR (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004058859	A1	20040325
APPLICATION INFO.:	US 2003-668400	A1	20030923 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-405986, filed on 27 Sep 1999, GRANTED, Pat. No. US 6676946 Continuation-in-part of Ser. No. US 1998-49847, filed on 27 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1998-EP1922	19980327
	US 1997-41726P	19970327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Charles A. Muserlian, c/o Muserlian, Lucas and  
Mercanti, 600 Third Avenue, New York, NY, 10016  
NUMBER OF CLAIMS: 42  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 2660  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A carbohydrate peptide conjugate comprising:

a carrier comprising a dendrimeric poly-Lysine enabling multiple  
epitopes to be covalently attachment thereto,

at least one peptide comprising one T epitope or several identical or  
different T epitopes,

at least one carbohydrate moiety, or a derivative thereof, containing B  
epitope provided it is not a sialoside, or several identical or  
different epitopes.

Use of this conjugate for inducing immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly colon cancer, are disclosed. Illustrative compositions  
comprise one or more colon tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly colon cancer.



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:225304 USPATFULL  
TITLE: MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE VACCINE  
COMPRISING THE SAME AND USE THEREOF  
INVENTOR(S): BAY, SYLVIE, PARIS, FRANCE  
CANTACUZONE, DANIELE, PARIS, FRANCE  
LECLERC, CLAUDE, PARIS, FRANCE  
LO-MAN, RICHARD, PARIS, FRANCE  
VICHER-GUERRE, SOPHIE, LA CELLE SAINT CLOUD, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157115	A1	20030821
	US 6676946	B2	20040113
APPLICATION INFO.:	US 1999-405986	A1	19990927 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-49847, filed on 27 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-EP9801922	19970327
	US 1997-41726P	19970327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MUSERLIAN AND LUCAS AND MERCANTI, LLP, 600 THIRD AVENUE, NEW YORK, NY, 10016	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	2528	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A carbohydrate peptide conjugate comprising:

a carrier comprising a dendrimeric poly-Lysine enabling multiple epitopes to be covalently attached thereto,

at least one peptide comprising one T epitope or several identical or different T epitopes,

at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not a sialoside, or several identical or different epitopes.

Use of this conjugate for inducing immune response.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of pancreatic cancer  
INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2003073144	A1	20030417	
APPLICATION INFO.:	US 2002-60036	A1	20020130	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 7 OF 10 USPATFULL on STN  
ACCESSION NUMBER: 2002:288104 USPATFULL  
TITLE: Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays  
INVENTOR(S): Banchereau, Jacques F., Dallas, TX, UNITED STATES  
Palucka, Anna Karolina, Dallas, TX, UNITED STATES  
Blanco, Patrick, Talence, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160974	A1	20021031
APPLICATION INFO.:	US 2002-42644	A1	20020108 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260541P	20010109 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Hale and Dorr LLP, 300 Park Avenue, New York, NY, 10022	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	1925	

AB The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

L42 ANSWER 8 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of ovarian cancer  
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 9 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:242791 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002131971	A1	20020919
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH	

AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L42 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2002:221953 USPATFULL  
TITLE: Enhanced stimulation of erythropoiesis  
INVENTOR(S): Bell, David, Oakville, CANADA  
Mueller, Susan G., Milton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002120098	A1	20020829
APPLICATION INFO.:	US 2001-985218	A1	20011009 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-917913, filed on 27 Aug 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24632P	19960827 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	2070	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compositions comprising heme-containing components and to methods that stimulate erythropoiesis comprising administration of a composition of the invention, such as purified hemoglobin. Surprisingly, heme-containing components such as hemoglobin can induce erythropoiesis in the presence of decreased concentrations of erythropoietin (Epo) and, in fact, functions synergistically with Epo. Further, heme-containing components can be used alone or in conjunction with Epo for the treatment of anemias and other disorders due to decreases in erythropoietin or iron. It has been discovered that, in the presence of Epo, both hemoglobin and cross-linked hemoglobin can compensate for the reduction in erythroid cell growth and differentiation that occurs in the presence of reduced concentrations of Epo. The effect is specific to erythropoiesis, as evidenced by a lack of growth of non-erythroid progenitors such as CFU-GM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.